GoAI
Get started
EDAP TMS S.A. American Depositary Shares logo

EDAP TMS S.A. American Depositary Shares

FOCL

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$4.13

−$0.11 · -2.59%

Aug 21, 4:00 PM ET

FOCL company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

78

Gaining

Sentiment

48

Mixed

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
FR
CEO
Ryan Rhodes
Listed since
Aug 1, 1997
Employees
289

Market position

Day range

Current $4.13

52-week range

Current $4.13

Open
$4.23
Previous close
$4.24
Volume
236.36K
2.98× average
Average volume
79.36K
Average daily volume
Market cap
154.8M USD
Beta
-0.03
Market reference 1
50-day average
$5.3384
-22.64% below average
200-day average
$4.0366
+2.32% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
130.42M USD
P/E (TTM)
-3.97×
P/B (TTM)
-48.06×
P/S (TTM)
2.24×
EV / EBITDA
-5.21×
Earnings yield
-23.82%
Free cash flow yield
-17.37%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
45.98%
Operating margin
-39.32%
Net margin
-56.25%
Return on equity
-151.12%
Return on assets
-37.14%
Return on invested capital
-49.23%

Financial health

Debt / equity
-12.37×
Current ratio
1.54×
Altman Z-score
-1.59
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends52%18%-16%-50%Gross margin, FY2021: 41.81%Gross margin, FY2022: 43.90%Gross margin, FY2023: 40.40%Gross margin, FY2024: 41.42%Gross margin, FY2025: 42.54%Operating margin, FY2021: -6.74%Operating margin, FY2022: -9.24%Operating margin, FY2023: -33.84%Operating margin, FY2024: -33.10%Operating margin, FY2025: -35.63%Net margin, FY2021: 1.59%Net margin, FY2022: -5.32%Net margin, FY2023: -35.05%Net margin, FY2024: -29.66%Net margin, FY2025: -41.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.81%. Gross margin FY2022 43.90%. Gross margin FY2023 40.40%. Gross margin FY2024 41.42%. Gross margin FY2025 42.54%. Operating margin FY2021 -6.74%. Operating margin FY2022 -9.24%. Operating margin FY2023 -33.84%. Operating margin FY2024 -33.10%. Operating margin FY2025 -35.63%. Net margin FY2021 1.59%. Net margin FY2022 -5.32%. Net margin FY2023 -35.05%. Net margin FY2024 -29.66%. Net margin FY2025 -41.47%.

Income trends

Revenue

70.75M USD+2.01%

Operating income

−25.21M USD-9.82%

Net income

−29.34M USD-42.61%
Income trends across reported periods80.75M USD40.72M USD688.02K USD−39.34M USDRevenue, FY2021: 52.08M USDRevenue, FY2022: 57.92M USDRevenue, FY2023: 65.32M USDRevenue, FY2024: 69.35M USDRevenue, FY2025: 70.75M USDOperating income, FY2021: −3.51M USDOperating income, FY2022: −5.35M USDOperating income, FY2023: −22.1M USDOperating income, FY2024: −22.95M USDOperating income, FY2025: −25.21M USDNet income, FY2021: 827.39K USDNet income, FY2022: −3.08M USDNet income, FY2023: −22.9M USDNet income, FY2024: −20.57M USDNet income, FY2025: −29.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 52.08M USD. Revenue FY2022 57.92M USD. Revenue FY2023 65.32M USD. Revenue FY2024 69.35M USD. Revenue FY2025 70.75M USD. Operating income FY2021 −3.51M USD. Operating income FY2022 −5.35M USD. Operating income FY2023 −22.1M USD. Operating income FY2024 −22.95M USD. Operating income FY2025 −25.21M USD. Net income FY2021 827.39K USD. Net income FY2022 −3.08M USD. Net income FY2023 −22.9M USD. Net income FY2024 −20.57M USD. Net income FY2025 −29.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue70.75M USD69.35M USD65.32M USD57.92M USD52.08M USD
Cost of goods sold40.65M USD40.63M USD38.93M USD32.49M USD30.31M USD
Gross profit30.09M USD28.73M USD26.39M USD25.43M USD21.77M USD
Research and development10.13M USD9.1M USD8.21M USD6.04M USD5.62M USD
Selling, general, and administrative45.17M USD42.58M USD40.28M USD24.73M USD19.66M USD
Operating expenses55.3M USD51.68M USD48.49M USD30.77M USD25.28M USD
Interest income252.78K USD861.03K USD1.42M USD424.59K USD11.82K USD
Interest expense791.44K USD255.28K USD250.82K USD176.56K USD61.46K USD
Depreciation and amortization3.43M USD2.8M USD2.08M USD1.72M USD2.27M USD
Operating income−25.21M USD−22.95M USD−22.1M USD−5.35M USD−3.51M USD
Net income−29.34M USD−20.57M USD−22.9M USD−3.08M USD827.39K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
33%
3 beats, 6 misses, 0 met estimates
Average EPS surprise
-16.54%
9 comparable reports
Latest EPS result
-0.39
Estimate -0.2 · Miss by 95.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-0.17-0.3-0.43Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.054, estimate -0.108, surprise +50.23%, Beat. Q2 2025, reported May 15, 2025: actual -0.213, estimate -0.164, surprise -29.30%, Miss. Q3 2025, reported Aug 28, 2025: actual -0.175, estimate -0.208, surprise +15.67%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.15, estimate -0.253, surprise +40.65%, Beat. Q1 2026, reported Mar 25, 2026: actual -0.255, estimate -0.148, surprise -72.34%, Miss. Q2 2026, reported May 7, 2026: actual -0.24, estimate -0.205, surprise -17.13%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.39, estimate -0.2, surprise -95.00%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.229, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates22.82M19.19M15.57M11.94MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 21.94M USD, estimate 20.85M USD, surprise +5.20%, Beat. Q2 2025, reported May 15, 2025: actual 15.17M USD, estimate 16.56M USD, surprise -8.39%, Miss. Q3 2025, reported Aug 28, 2025: actual 18.72M USD, estimate 15.82M USD, surprise +18.35%, Beat. Q4 2025, reported Nov 6, 2025: actual 16.02M USD, estimate 15.04M USD, surprise +6.45%, Beat. Q1 2026, reported Mar 25, 2026: actual 21.91M USD, estimate 21.34M USD, surprise +2.64%, Beat. Q2 2026, reported May 7, 2026: actual 17.81M USD, estimate 16.59M USD, surprise +7.39%, Beat. Q3 2026, reported Aug 13, 2026: actual 13.2M USD, estimate 15.09M USD, surprise -12.49%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 12.82M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$9.50

130.02% upside
Past 12 months12-month forecastHigh $15.00Average $9.50Low $4.00

Recent analyst actions

1 institution

FOCL news

defenseworld.net

Analysts Set FocalTherics (NASDAQ:FOCL) Target Price at $9.00

FocalTherics (NASDAQ: FOCL - Get Free Report) has earned a consensus recommendation of "Hold" from the five analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell…

Read source
seekingalpha.com

EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript

EDAP TMS S.A. (FOCL) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

FocalTherics Q2 Earnings Call Highlights

FocalTherics NASDAQ: FOCL reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound…

Read source
globenewswire.com

FocalTherics™ Reports Second Quarter 2026 Financial Results

FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global…

Read source
globenewswire.com

FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares

FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic…

Read source
globenewswire.com

FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026

FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy,…

Read source

FOCL peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research FOCL

research.disclaimer